Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,703.0 02/08/16
52 week low1,575.0 04/11/16
52 week change 233.0 (12.42%)
4 week volume12,480,067 29/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Hikma inks licensing deal with Orion for Easyhaler

Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland, f...

Licensing agreement with Orion for Easyhaler?

RNS Number: 7211W Hikma Pharmaceuticals Plc 13 February 2017 PRESS RELEASE Hikma announces exclusive licensing agreement with Orion for its new Easyhaler product in MENA London, 13 February 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, toda...

Total Voting Rights

RNS Number: 1406W Hikma Pharmaceuticals Plc 06 February 2017 Hikma Pharmaceuticals PLC Voting Rights and Capital LONDON, 6 February 2017, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 239,971,020 ordinary shares with voting rights. There are nil shares held in treasury. The above figure may...

Holding(s) in Company

RNS Number: 1324W Hikma Pharmaceuticals Plc 06 February 2017 Notification of major interests in shares LONDON, 6 February 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows: 1 Identity of the issuer or the underlying issuer of existing shares to which the voting ...

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today initiates coverage of Hikma Pharmaceuticals PLC (LON:HIK) with a buy investment rating and price targ...

Hikma unit gets FDA approval for narcolepsy drug

Hikma Pharmaceuticals' wholly-owned US subsidiary, Roxane Laboratories, has received an approval for its generic equiv...

Hikma receives approval for Sodium Oxybate

RNS Number: 4587U Hikma Pharmaceuticals Plc 18 January 2017 Hikma receives approval for Sodium Oxybate Oral Solution London, 18 January 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its whol...

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cu...

Latest discussion posts More

  • Re: Update

    Thanks for the update Fred, and glad you can tear yourself away from winding everybody up on the IGG board. (They don't like you there do they? What a shame iii did away with ...
    12-Feb-2017
    Hardboy
  • Update

    Hi guys, have been busy with projects recently but FYI I just came off the phone with the spread better and as we have not spoke for a few weeks since he sold out, he informed ...
    11-Feb-2017
    Fred Prior
  • Re: Holding

    Thanks
    8-Feb-2017
    paul1945

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.30%
GLAXOSMITHKLINE27%
RDS 'B'25%
VODAFONE GRP.24%
BP23%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK